----------------

SEMINAR 1

----------------

Title（题目）：客户决策管理的技术创新 - 量化决策管理

Time（时间）：2011年3月24日（周四）下午2:00－3:00

Place（地点）：成人直播-成人直播室 新楼217教室

Speaker（报告人）：Mr. Yachen Lin 广发银行首席风险官

Abstract（摘要）：

客户的行为表现可以表示成一个多维数据向量，巨大数量的客户行为构成了一个多维向量的海量数据。基于客户行为、即这海量数据、怎样才能使商业决策做到有的放矢、精准客观、最终极大化决策回报？答案是量化决策管理。

量化决策管理是目前世界上最先进的决策管理方法。那么，什么是量化决策管理？它的核心技术是什么？它的发展趋势和市场价值怎样？它在中国大陆应用又如何呢？这些问题都将在这次的报告中得到回答。

----------------

SEMINAR 2

----------------

Title（题目）：Development of analytic methods for genome-scale RNAi screens

Time（时间）：2011年3月24日（周四）下午3:30－4:30

Speaker（报告人）：Xiaohua Douglas Zhang, Ph.D.

Associate Director, Department of Biometrics Research

Merck Research Laboratories

Abstract（摘要）：

RNA interference (RNAi) is a mechanism in living cells that helps determine what genes are active and how active they are. The development of algorithms for RNAi design that produce potent and selective knockdown of targeted genes has led to a great deal of interest in using RNAi to elucidate gene function, to identify novel targets for drug discovery, and to reveal the molecular biological system. The importance of RNAi was further recognized when the Nobel Prize in Medicine and Physiology was awarded to Drs. Fire and Mello in 2006 for their research in this field. The genome-scale RNAi study allows genome-wide loss-of-function screening. One of the major advantages of the genome-scale RNAi researches is their ability to simultaneously interrogate thousands of genes. With the ability of generating a large amount of data per experiment, the genome-scale RNAi researches have led to an explosion in the rate of data generated in recent years. Consequently, one of the most fundamental challenges in the genome-scale RNAi researches is to glean biological significance from mounds of data, which relies on the development and adoption of statistics/bioinformatics methods that are suitable for analyzing RNAi screens. Recently, we have been developing novel analytic methods specifically for quality control and hit selection in genome-scale RNAi screens. I will present these recently developed analytic methods and demonstrate how to use them in RNAi high-throughput screens.

About the speaker（报告人介绍）：

Dr. Xiaohua Douglas Zhang is an Associate Director, Scientific Staff, in Merck Research Laboratories. He got his Ph.D. in statistics from Carnegie-Mellon University, PA, USA, an MS in Genetics and a BS in Biology from Beijing Normal University, China. He has worked on analyzing data generated from new biotechnologies. He has analyzed many high-throughput screening (HTS) projects for many years. Merck has put great effort into RNAi research. It purchased Sirna for $1.1 billion in 2006 and has one of the largest labs for conducting RNAi/compound HTS. Since early 2005, Dr. Zhang has led data analysis in RNAi HTS projects at Merck and has continuously developed and adopted experimental designs and analytic methods for HTS projects including novel analytic methods for quality controls and hit selection, which allows him and his colleagues to continuously publish papers in t